<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739124</url>
  </required_header>
  <id_info>
    <org_study_id>2020PPRC11</org_study_id>
    <nct_id>NCT04739124</nct_id>
  </id_info>
  <brief_title>Appropriation of the Connected Solution Freestyle Libre® in Adult Patients With Diabetes in the Context of Therapeutic Education</brief_title>
  <acronym>APPRO-FSL</acronym>
  <official_title>Appropriation of the Connected Solution Freestyle Libre® in Adult Patients With Diabetes in the Context of Therapeutic Education</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following the proposal to self-monitor by the Freestyle Libre® (FSL) connected object, in&#xD;
      diabetic patients in the context of therapeutic education, regarding the appropriation of&#xD;
      FSL, what works, for which patients , in what specific contexts and by what mechanisms does&#xD;
      it govern? A multicentric observational research will be conducted with mixed method design&#xD;
      (follow-up using patient questionnaires) and semi-structured interviews of patients and&#xD;
      caregivers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between appropriation factors, intention to use, Freestyle Libre use and glycemic control</measure>
    <time_frame>3 months</time_frame>
    <description>longitudinal multifactor analysis by structural equation modeling of the research model created specifically</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Diabetic patients</arm_group_label>
    <description>Patients presenting type 1 or type 2 diabetes, eligible for the prescription of Freestyle Libre</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caregivers</arm_group_label>
    <description>Caregiver caring for diabetic patients and practicing therapeutic education on a regular basis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up questionnaires</intervention_name>
    <description>The patient normally follows the education program as usual but research specific data is collected:&#xD;
Biological sampling at the start and end of the education program (glycated hemoglobin).&#xD;
Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)&#xD;
Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)</description>
    <arm_group_label>Caregivers</arm_group_label>
    <arm_group_label>Diabetic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interviews</intervention_name>
    <description>Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.</description>
    <arm_group_label>Diabetic patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be composed of diabetic patients and their caregivers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients&#xD;
&#xD;
               -  Have type 1 or type 2 diabetes (as included in the education program),&#xD;
&#xD;
               -  Be of legal age (over 18 years old),&#xD;
&#xD;
               -  Do not present legal protection measures due to incapacity (such as guardianship&#xD;
                  or guardianship).&#xD;
&#xD;
               -  Be able to read and speak French (elementary school level)&#xD;
&#xD;
               -  Be eligible for FSL prescription and authorize the sharing of your data in&#xD;
                  Libreview®&#xD;
&#xD;
               -  Be affiliated to a social security scheme&#xD;
&#xD;
               -  Have an email address or a phone allowing internet use&#xD;
&#xD;
          -  Caregivers&#xD;
&#xD;
               -  Be registered on the roll of his professional order&#xD;
&#xD;
               -  Hold the certificate of 40 hours of training in therapeutic education.&#xD;
&#xD;
               -  Practice therapeutic education on a regular basis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients&#xD;
&#xD;
               -  presenting contraindications to the use of Freestyle Libre® (known allergies to&#xD;
                  adhesive products, coagulation disorders, not treated with insulin therapy or&#xD;
                  with less than 3 insulin injections per day or continuously, not requiring&#xD;
                  glycemic monitoring or less than 3 times a day)&#xD;
&#xD;
               -  Patient refusing to follow the education program,&#xD;
&#xD;
               -  Minors, patients under administrative or judicial supervision)&#xD;
&#xD;
               -  Pregnant women,&#xD;
&#xD;
               -  Patients who cannot be contacted in an emergency,&#xD;
&#xD;
               -  Persons in a position to give their consent but with an inability to read / write&#xD;
                  the French language.&#xD;
&#xD;
               -  Patients who do not have an email address or a phone allowing internet use.&#xD;
&#xD;
          -  Caregivers&#xD;
&#xD;
               -  Failure to register with the professional order (except those of the Army Health&#xD;
                  Service who are exempt)&#xD;
&#xD;
               -  Non-possession of the 40-hour therapeutic education training certificate.&#xD;
&#xD;
               -  Not practicing FSL education&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lyse Bordier, MD,PhD</last_name>
    <phone>143985983</phone>
    <phone_ext>33</phone_ext>
    <email>lyse.sirvin@intradef.gouv.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien Bouix, MSc</last_name>
    <phone>140514656</phone>
    <phone_ext>33</phone_ext>
    <email>julien.bouix@intradef.gouv.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Bihan, MD</last_name>
      <phone>148955585</phone>
      <phone_ext>33</phone_ext>
      <email>helene.bihan@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aurore Margat</last_name>
      <phone>615021641</phone>
      <phone_ext>33</phone_ext>
      <email>aurore.margat@univ-paris13.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital d'Instruction des Armées Bégin</name>
      <address>
        <city>Saint Mande</city>
        <zip>94163</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyse BORDIER, MD, PhD</last_name>
      <phone>143985983</phone>
      <phone_ext>33</phone_ext>
      <email>lyse.sirvin@intradef.gouv.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien BOUIX, MSc</last_name>
      <phone>140514656</phone>
      <phone_ext>33</phone_ext>
      <email>julien.bouix@intradef.gouv.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

